News

NovaDel Pharma (NovaDel) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for claims under US Patent Application No 10/671,715, entitled; Buccal, Polar

Bristol-Myers Squibb has reported that FDA has approved a labeling update for Reyataz to include long-term data from the Castle study. The Castle study assessed a once-daily Reyataz/ritonavir

Abraxis BioScience’s chemotherapy agent, ABRAXANE for injectable suspension, has received orphan drug designation from the Office of Orphan Products Development of the FDA. It is intended for the

The study was aimed at comparing the bioavailability and pharmacokinetics of cyclosporine after intravenous administration of NeuroSTAT, a Cremophor EL-free lipid emulsion, and Sandimmune Injection in healthy volunteers.

According to the CMS Industry Report 2009, Chemical Management Services (CMS) providers reported 30% revenue growth per year between 2006-2008 by helping their customers significantly reduce their chemical

SAIC-Frederick has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of

Amgen has reported that the Phase 3 PRIME 203 trial evaluating Vectibix (panitumumab) administered in combination with Folfox (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal

Ligand Pharmaceuticals has extended its research collaboration with Pfizer for JAK3 by one year. The research and license agreement entered with Wyeth provided for an initial three year

Phase Forward has entered into a multi-year agreement with Quotient Clinical, a strategic business unit of Quotient Bioresearch (Quotient). Quotient is implementing Phase Forward’s InForm Global Trial Management